AbstractPediatric and adolescent obesity commonly coexist with stress‐related symptoms and disorders. Stress, the state of threatened homeostasis, is associated with the acute activation of the hypothalamic–pituitary–adrenal axis and the sympathetic nervous system. However, the chronic activation of hypothalamic–pituitary–adrenal and sympathetic nervous system axes during chronic or intense stress can lead to a variety of psychopathological and physical conditions. Behavioral and neurobiological mechanisms link chronic stress with pediatric obesity, in a bidirectional relation. Chronically stressed individuals are characterized by low adherence to a healthy lifestyle and by disturbed eating behaviors, whereas alterations in the secretion of stress hormones might also contribute to obesity and obesity‐related complications. Obesity could lead to increased social distress, low self‐esteem, and anxiety, thereby contributing to a vicious cycle between distress and obesity and increasing further the risk of cardiometabolic morbidity. This review article summarizes recent research findings and discusses mechanisms linking stress with pediatric obesity.
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
In: Vlahou , A , Hallinan , D , Apweiler , R , Argiles , A , Beige , J , Benigni , A , Bischoff , R , Black , P C , Boehm , F , Céraline , J , Chrousos , G P , Delles , C , Evenepoel , P , Fridolin , I , Glorieux , G , van Gool , A J , Heidegger , I , Ioannidis , J P A , Jankowski , J , Jankowski , V , Jeronimo , C , Kamat , A M , Masereeuw , R , Mayer , G , Mischak , H , Ortiz , A , Remuzzi , G , Rossing , P , Schanstra , J P , Schmitz-Dräger , B J , Spasovski , G , Staessen , J A , Stamatialis , D , Stenvinkel , P , Wanner , C , Williams , S B , Zannad , F , Zoccali , C & Vanholder , R 2021 , ' Data Sharing Under the General Data Protection Regulation : Time to Harmonize Law and Research Ethics? ' , Hypertension , vol. 77 , no. 4 , pp. 1029-1035 . https://doi.org/10.1161/HYPERTENSIONAHA.120.16340
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research ...
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.
In: Vlahou , A , Hallinan , D , Apweiler , R , Argiles , A , Beige , J , Benigni , A , Bischoff , R , Black , P C , Boehm , F , Céraline , J , Chrousos , G P , Delles , C , Evenepoel , P , Fridolin , I , Glorieux , G , van Gool , A J , Heidegger , I , Ioannidis , J P A , Jankowski , J , Jankowski , V , Jeronimo , C , Kamat , A M , Masereeuw , R , Mayer , G , Mischak , H , Ortiz , A , Remuzzi , G , Rossing , P , Schanstra , J P , Schmitz-Dräger , B J , Spasovski , G , Staessen , J A , Stamatialis , D , Stenvinkel , P , Wanner , C , Williams , S B , Zannad , F , Zoccali , C & Vanholder , R 2021 , ' Data Sharing Under the General Data Protection Regulation Time to Harmonize Law and Research Ethics? Time to Harmonize Law and Research Ethics? ' , Hypertension , vol. 77 , no. 4 , pp. 1029-1035 . https://doi.org/10.1161/HYPERTENSIONAHA.120.16340 ; ISSN:0194-911X
The General Data Protection Regulation (GDPR) became binding law in the European Union Member States in 2018, as a step toward harmonizing personal data protection legislation in the European Union. The Regulation governs almost all types of personal data processing, hence, also, those pertaining to biomedical research. The purpose of this article is to highlight the main practical issues related to data and biological sample sharing that biomedical researchers face regularly, and to specify how these are addressed in the context of GDPR, after consulting with ethics/legal experts. We identify areas in which clarifications of the GDPR are needed, particularly those related to consent requirements by study participants. Amendments should target the following: (1) restricting exceptions based on national laws and increasing harmonization, (2) confirming the concept of broad consent, and (3) defining a roadmap for secondary use of data. These changes will be achieved by acknowledged learned societies in the field taking the lead in preparing a document giving guidance for the optimal interpretation of the GDPR, which will be finalized following a period of commenting by a broad multistakeholder audience. In parallel, promoting engagement and education of the public in the relevant issues (such as different consent types or residual risk for re-identification), on both local/national and international levels, is considered critical for advancement. We hope that this article will open this broad discussion involving all major stakeholders, toward optimizing the GDPR and allowing a harmonized transnational research approach.